A peptide PDMHS2 that can improve insulin secretion and proliferation function
By screening out the peptide PDMHS2, the problems of inconsistent treatment effects and poor patient compliance in gestational hypothyroidism have been solved. It promotes the proliferation of pancreatic islet cells and insulin secretion in offspring of gestational hypothyroidism, improves metabolic problems caused by hypothyroidism, and provides a new strategy for the treatment of gestational hypothyroidism and diabetes.
Patent Information
- Application Number
- CN202410918663.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-10
AI Technical Summary
Existing medications for treating hypothyroidism during pregnancy, such as levothyroxine, have inconsistent therapeutic effects, poor patient compliance, unknown effects on offspring glucose metabolism abnormalities, and may lead to drug intolerance. Regular monitoring of thyroid hormone levels is necessary to adjust the dosage.
The peptide PDMHS2 was screened from serum of pregnant women with hypothyroidism. This peptide is highly conserved among species and promotes the expression of THRβ, insulin, and the proliferation-related gene Ki67 in the pancreatic islet cells of pregnant women with hypothyroidism. It regulates islet cell function by affecting the DNA methylation modification of the target gene THRβ by DNMT3A.
The peptide PDMHS2 can promote the proliferation of pancreatic islet cells and insulin secretion in offspring of gestational hypothyroidism, improve metabolic problems caused by hypothyroidism, and provide a new treatment strategy suitable for the treatment of gestational hypothyroidism and diabetes. It has high conservation and stability and can directly act on pancreatic islet cells.
Smart Images

Figure CN118459570B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular, relates to a polypeptide PDMHS2 capable of improving insulin secretion and proliferation functions. Background Art
[0002] At present, the first choice drug for treating hypothyroidism during pregnancy is levothyroxine (Euthyrox). Although it can achieve certain treatment goals, the treatment effects are mixed. Patients may have drug intolerance and need to monitor thyroid hormone levels regularly to adjust the dosage. Patient compliance is poor, and its effect on reducing abnormal glucose metabolism in offspring is unknown. Therefore, it is of great clinical significance to actively explore the mechanism of abnormal glucose metabolism in offspring of hypothyroidism during pregnancy and find effective prevention and treatment methods.
[0003] Islet cell dysfunction and insulin resistance in peripheral tissues (liver, skeletal muscle, fat, etc.) are important mechanisms for the development of diabetes. Poor nutrition or environment during pregnancy mainly regulates the glucose metabolism of offspring through epigenetic mechanisms such as DNA methylation, histone modification, and microRNA. Thyroid hormones can promote the proliferation and maturation of pancreatic β cells and the expression and secretion of insulin by binding to nuclear receptor transcription factors THRα (Thyroidhormone receptor α) and THRβ (Thyroid hormone receptor β) and acting on downstream target genes; they can also act on peripheral tissues (liver, skeletal muscle, fat, etc.) to regulate insulin resistance. Hypothyroidism in pregnant mice can lead to adaptive downregulation of the THRβ gene in pancreatic tissue of offspring, reduced proliferation of pancreatic β cells and reduced insulin gene expression, glucose intolerance, reduced insulin secretion, reduced activity of glucokinase (Glucokinase) and hexokinase (Hexokinase) in the pancreas, and reduced glucose tolerance in offspring. Drugs that act on THRβ in pancreatic cells may improve the abnormal glucose metabolism of offspring with hypothyroidism during pregnancy.
[0004] Peptides are a class of active substances that are commonly found in organisms and are composed of more than two amino acid molecules. They have the advantages of small molecular weight, simple synthesis, low immunogenicity, and high tissue penetration, and are valued in drug research and development in many fields. At present, there are more than 100 peptide drugs on the market worldwide for the treatment of tumors, obesity, infections and other diseases. The application of dulaglutide and liraglutide in the treatment of diabetes shows the great application value of peptides. Exploring new components that regulate glucose metabolism in offspring of gestational hypothyroidism from the perspective of peptides may find new breakthroughs. Summary of the invention
[0005] In view of this, in order to overcome the above technical problems existing in the art, the inventors of the present invention screened and obtained a differentially low-expressed polypeptide PDMHS2 from the serum of gestational hypothyroidism. The polypeptide PDMHS2 is highly conserved among species, has high stability, and can enter pancreatic islet cells. It has the effect of promoting the expression of THRβ, insulin, and proliferation-related gene Ki67 in the offspring pancreatic islet cells of gestational hypothyroidism.
[0006] The present invention adopts the following technical solutions to achieve the above-mentioned invention objectives:
[0007] The first aspect of the present invention provides a polypeptide or a pharmaceutically acceptable salt thereof.
[0008] Furthermore, the amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1 or has at least 90% sequence homology with SEQ ID NO: 1.
[0009] In some embodiments, the pharmaceutically acceptable salt of the polypeptide refers to the acid salt formed by the polypeptide with inorganic and / or organic acids and the basic salt formed with inorganic and / or organic bases. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, but other salts are also useful. The pharmaceutically acceptable salt of the polypeptide can be formed, for example, by the following method: reacting the polypeptide with a certain amount of acid or base in a medium, such as a medium in which the salt is precipitated or an aqueous medium (freeze-dried after the reaction).
[0010] Specific pharmaceutically acceptable salts include those salts which are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction, etc., and which are commensurate with a reasonable benefit or risk ratio within the scope of sound medical judgment. Pharmaceutically acceptable salts (pharmaceutically acceptable salts) are well known in the art. Pharmaceutically acceptable salts of the polypeptides of the present invention include salts derived from suitable inorganic and organic acids and inorganic and organic bases.
[0011] In some embodiments, suitable acids for preparing pharmaceutically acceptable salts of the polypeptide include, but are not limited to, acetic acid, 2,2-dichloroacetic acid, lauric acid, maleic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, nicotinic acid, nitric acid, oleic acid, orotic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, malonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, 1,5-naphthalene disulfonic acid, 1-hydroxy-2-naphthalenecarboxylic acid, oxalic acid, palmitic acid, capric acid, hexanoic acid, caprylic acid, cinnamic acid, citric acid, Citric acid, cyclamic acid, cyclohexylaminosulfonic acid, dodecylsulfuric acid, 1,2-ethanedisulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, α-ketoglutaric acid, glycolic acid, hippurate, hydrobromic acid, hydrochloric acid, hydroiodic acid, (+)-L-lactic acid, (-)-L-malic acid, phosphoric acid, L-pyroglutamic acid, glucaric acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid and / or valeric acid.
[0012] In some embodiments, suitable bases for preparing pharmaceutically acceptable salts of the polypeptide include, but are not limited to, inorganic bases such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide and / or sodium hydroxide; organic bases such as primary, secondary, tertiary, butyl, aliphatic and aromatic amines including: L-arginine, phenethylbenzylamine, benzylethylenediamine, choline, dimethylaminoethanol, diethanolamine, diethylamine, dimethylamine, propylamine, diisopropylamine, diethylaminoethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, meglumine, hydrabamine, 1H-imidazole, L-lysine, morpholin, 4-(2-hydroxyethyl)morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, 1-(2-hydroxyethyl)pyrrolidine, pyridine, quinuclidine, quinoline, isoquinoline, secondary amines, triethanolamine, trimethylamine, triethylamine, N-methyl-D-glucamine, trishydroxymethylaminomethane and / or tromethamine.
[0013] In the present invention, sequences corresponding to polypeptides having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% sequence homology with the amino acid sequence of the polypeptide as described above of the present invention are all within the protection scope of the present invention.
[0014] In a specific embodiment of the present invention, the polypeptide is PDMHS2, which affects the expression of the target gene THRβ by affecting the DNA methylation modification of the target gene THRβ by DNMT3A, thereby affecting the proliferation of pancreatic β cells and the level of insulin synthesis.
[0015] The second aspect of the present invention provides a polynucleotide.
[0016] Furthermore, the polynucleotide encodes the polypeptide described in the first aspect of the present invention.
[0017] In some embodiments, the polynucleotides can be synthesized by standard chemical synthesis methods and / or recombinant methods, or semi-synthetically produced, for example, by combining chemical synthesis and recombinant methods. The connection of the coding sequence to the transcriptional regulatory elements and / or to other amino acid coding sequences can be carried out using methods well known in the art, such as restriction enzyme digestion, connection and molecular cloning.
[0018] In the present invention, variants of the above polynucleotides are also included in the scope of protection of the present invention. The variants of the polynucleotides are variants that differ from the above polynucleotides by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in the coding region or in the non-coding region or in both. Changes in the coding region may produce conservative or non-conservative amino acid substitutions, deletions or additions.
[0019] The third aspect of the present invention provides a vector.
[0020] Furthermore, the vector comprises the polynucleotide described in the second aspect of the present invention.
[0021] In some embodiments, the vector also includes a transcription promoter and an optionally present enhancer, a translation signal, and a transcription and translation termination signal. Expression vectors for stable transformation generally have a selectable marker that allows selection and maintenance of transformed cells. In some cases, a replication origin can be used to amplify the number of copies of the vector in the cell. The vector can also include additional nucleotide sequences that are operably linked to a target nucleic acid molecule, such as an epitope tag for localization, such as a 6-his tag or a myc tag, or a tag for purification, such as a GST fusion; and sequences for directing protein secretion and / or membrane association.
[0022] In the present invention, there is no particular limitation on the type of vector, which may be a vector capable of replicating and / or expressing a polynucleotide in eukaryotic or prokaryotic cells including mammalian cells (e.g., human, monkey, rabbit, rat, hamster or mouse cells), yeast cells, insect cells and bacteria (e.g., E. coli). Preferably, the vector comprises at least one selective marker, operably linked to a suitable promoter, so that the polynucleotide can be expressed in the host cell. For example, the vector may include a bacteriophage, a plasmid, a cosmid, a minichromosome, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a poxvirus vector and / or a herpesvirus vector, which are conventionally used in, for example, genetic engineering.
[0023] A fourth aspect of the present invention provides a host cell.
[0024] Furthermore, the host cell comprises the vector described in the third aspect of the present invention.
[0025] In some embodiments, the host cell is a cell for receiving, maintaining, replicating and amplifying the vector. The host cell can also be used to express the polypeptide encoded by the vector. When the host cell divides, the nucleic acid contained in the vector replicates, thereby amplifying the nucleic acid.
[0026] In the present invention, there is no particular limitation on the host cells. Exemplarily, the host cells include but are not limited to: CHO-K1, DUkXB11, Pro-5, CHO-S, mouse myeloma cells NSO, mouse myeloma cells SP2 / 0-Ag14, rat myeloma cells YB2 / 0, mouse P3-X63-Ag8653 cells, CHO cells defective in the dihydrofolate reductase gene, Lec13 with lectin resistance, CHO cells defective in the α1,6-fucosyltransferase gene, rat YB2 / 3HL.P2.G11.16Ag.20 cells, CHO-3E7 cells, immune cells or any combination thereof.
[0027] The fifth aspect of the present invention provides a polypeptide derivative.
[0028] Furthermore, the polypeptide derivatives include polypeptide derivatives obtained by modifying the polypeptide described in the first aspect of the present invention or polypeptide derivatives obtained by connecting a conjugate to the polypeptide described in the first aspect of the present invention.
[0029] Further, the modification includes hydrophobic group modification, glycosylation modification, esterification modification, amidation modification, pegylation modification, acetylation modification, alkylation modification, amination modification, methylation modification, hydroxylation modification, carboxylation modification, carbonylation modification, phosphorylation modification, sulfation modification and / or cyclization modification;
[0030] The conjugates include radioactive compounds, fluorescent dyes, metal ions, enzymes and / or cell penetrating peptides.
[0031] In some embodiments, the polypeptide derivative of the present invention can be a polypeptide derivative obtained by modifying the N-terminus of the polypeptide described in the first aspect of the present invention with a hydrophobic group. Exemplarily, the hydrophobic group includes, but is not limited to, any one or more combinations of myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol and arachidonic acid.
[0032] In some embodiments, the polypeptide derivative of the present invention may be a polypeptide derivative obtained by connecting a cell penetrating peptide to the N-terminus of the polypeptide described in the first aspect of the present invention. Cell penetrating peptides are also called targeting peptides, protein transduction domains, Trojan horse peptides, etc., which are a large class of short amino acid sequences (5-30 residues) that can pass through biological membranes and deliver a variety of compounds into cells, including small molecules, nucleic acids, proteins, viruses, imaging agents and drugs, etc. The cell penetrating peptides of the present invention include any cell penetrating peptides known in the art.
[0033] In some embodiments, the conjugate can be a detection agent, which can be any substance with detectable physical or chemical properties. Exemplary detection agents include but are not limited to fluorescent dyes (e.g., fluorescein isothiocyanate, Texas Red, rhodamine, etc.), radioactive labels (e.g., 3 H. 125 I. 35 S. 14 C or 32 P, etc.), in particular, radiolabeled (e.g. 157 Gd, 55 Mn, 162 Dy, 52 Cr or 56 Fe, etc.), metal ions (e.g. 111 In, 97 Such as 67 Ga, 68 Ga, 72 As, 89 Zr or 201 Tl, etc.), enzymes (e.g., horseradish peroxidase, alkaline phosphatase, and other enzymes commonly used in ELISA), electron transfer agents (e.g., metal binding proteins, etc.), luminescent and chemiluminescent labels (e.g., fluorescein, 2,3-dihydrophthalazine, or luminol, etc.), magnetic beads, and colorimetric labels, such as colloidal gold or colored glass or plastic beads (e.g., polystyrene or polypropylene, etc.).
[0034] The sixth aspect of the present invention provides a pharmaceutical composition.
[0035] Furthermore, the pharmaceutical composition comprises the polypeptide or pharmaceutically acceptable salt thereof described in the first aspect of the present invention, the polynucleotide described in the second aspect of the present invention, the vector described in the third aspect of the present invention, the host cell described in the fourth aspect of the present invention and / or the polypeptide derivative described in the fifth aspect of the present invention.
[0036] In some embodiments, the pharmaceutical composition may further comprise other drugs that can be used to treat and / or prevent diseases related to abnormal glucose metabolism or diseases related to hypothyroidism. Any drug currently known in the art that can be used to treat and / or prevent diseases related to abnormal glucose metabolism or diseases related to hypothyroidism is within the scope of protection of the present invention.
[0037] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient. Exemplarily, the pharmaceutically acceptable carrier and / or excipient include, but are not limited to, a diluent, a binder, a surfactant, a humectant, an adsorption carrier, a lubricant, a filler, and a disintegrant.
[0038] In some embodiments, the diluent includes but is not limited to: lactose, sodium chloride, glucose, urea, starch, water, etc. The binder includes but is not limited to: starch, pregelatinized starch, dextrin, maltodextrin, sucrose, gum arabic, gelatin, methylcellulose, carboxymethylcellulose, alginic acid and alginate, xanthan gum, hydroxypropyl cellulose, etc. The surfactant includes but is not limited to: sodium lauryl sulfate, stearic acid monoglyceride, hexadecanol, etc. The humectant includes but is not limited to: glycerol, starch, etc. The adsorption carrier includes but is not limited to: starch, lactose, bentonite, soap clay, etc. The lubricant includes but is not limited to: zinc stearate, talc, calcium and magnesium stearate, polyethylene glycol, polyoxyethylene monostearate, monolauric sucrose acid ester, magnesium lauryl sulfate, etc. The filler includes but is not limited to: mannitol, xylitol, sorbitol, maltose, glucose, lactose, sucrose, dextrin, starch, etc. The disintegrants include, but are not limited to, cross-linked vinyl pyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl methyl, cross-linked sodium carboxymethyl cellulose, soybean polysaccharides, and the like.
[0039] A seventh aspect of the present invention provides a pharmaceutical preparation.
[0040] Furthermore, the pharmaceutical preparation comprises the pharmaceutical composition described in the sixth aspect of the present invention.
[0041] In some embodiments, the dosage form of the pharmaceutical preparation includes a dosage form for administration through the gastrointestinal tract and a dosage form for administration through the parenteral tract. Exemplarily, the dosage form for administration through the gastrointestinal tract includes, but is not limited to, tablets, granules, capsules, solutions, dry suspensions, powders, sustained-release agents, effervescent agents, emulsions, suspensions, syrups, drops, and chewables, and the dosage form for administration through the parenteral tract includes, but is not limited to, injection dosage forms, respiratory tract dosage forms, cavity dosage forms, mucosal dosage forms, and skin dosage forms.
[0042] In some embodiments, the injection dosage forms include but are not limited to: intravenous injections, intramuscular injections, subcutaneous injections, intradermal injections and intracavitary injections; the respiratory tract administration dosage forms include but are not limited to: sprays, aerosols, powder aerosols, etc.; the cavity administration dosage forms include but are not limited to: suppositories, aerosols, effervescent tablets, drops, pills, etc., used in the rectum, vagina, urethra, nasal cavity, ear canal, etc.; the mucosal administration dosage forms include but are not limited to: eye drops, nasal drops, eye ointments, gargles, sublingual tablets, adhesive tablets, patches, etc.; the skin administration dosage forms include but are not limited to: external solutions, lotions, liniments, ointments, plasters, pastes, patches, etc.
[0043] In some embodiments, the suitable dosage of the drugs, pharmaceutical compositions or pharmaceutical preparations provided by the present invention can be prescribed in a variety of ways according to the formulation method, administration method, patient's age, weight, gender, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity and other factors. A skilled physician can usually easily determine the prescription and the desired effective dosage for treatment. As long as it can produce the expected therapeutic and / or preventive effect on the disease or related symptoms, such dosage is within the scope of protection of the present invention.
[0044] The eighth aspect of the present invention provides any of the following applications:
[0045] (1) Use of the polypeptide or pharmaceutically acceptable salt thereof according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention and / or the polypeptide derivative according to the fifth aspect of the present invention in the preparation of a medicament for treating and / or preventing hypothyroidism during pregnancy;
[0046] (2) Use of the polypeptide or pharmaceutically acceptable salt thereof according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention and / or the polypeptide derivative according to the fifth aspect of the present invention in the preparation of a medicament for treating and / or preventing diabetes;
[0047] (3) Use of the polypeptide or pharmaceutically acceptable salt thereof according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention and / or the polypeptide derivative according to the fifth aspect of the present invention in the preparation of a medicament for improving hypothyroidism;
[0048] (4) Use of the polypeptide or pharmaceutically acceptable salt thereof according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention and / or the polypeptide derivative according to the fifth aspect of the present invention in the preparation of a medicament for improving abnormal glucose metabolism or blood glucose level;
[0049] (5) Use of the polypeptide or pharmaceutically acceptable salt thereof according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention and / or the polypeptide derivative according to the fifth aspect of the present invention in the preparation of a medicament for increasing insulin expression;
[0050] (6) Use of the polypeptide or pharmaceutically acceptable salt thereof according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention and / or the polypeptide derivative according to the fifth aspect of the present invention in the preparation of a medicament for promoting pancreatic cell proliferation;
[0051] (7) Use of the polypeptide or pharmaceutically acceptable salt thereof according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, the vector according to the third aspect of the present invention, the host cell according to the fourth aspect of the present invention and / or the polypeptide derivative according to the fifth aspect of the present invention in the preparation of an agent for promoting the expression of Ki67, THRβ1, THRβ2 and / or Insulin in pancreatic islet cells.
[0052] In the present invention, the treatment and / or prevention refers to delaying the development of a disease, preventing the development of a disease, and / or reducing the severity of the symptoms that will develop or are expected to develop. Therefore, these terms include improving existing disease symptoms, preventing additional symptoms, improving or preventing potential metabolic causes of symptoms, inhibiting a disorder or disease, for example, preventing the development of a disorder or disease, alleviating a disorder or disease, regressing a disorder or disease, alleviating a condition caused by a disease or disorder, or stopping symptoms of a disease or disorder.
[0053] A ninth aspect of the present invention provides any of the following methods:
[0054] (1) A method for producing the polypeptide described in the first aspect of the present invention, the method comprising the following steps: culturing the host cell described in the fourth aspect of the present invention, and isolating the polypeptide described in the first aspect of the present invention from the cell culture obtained by culturing;
[0055] (2) A method for preparing the host cell according to the fourth aspect of the present invention, the method comprising the following steps: introducing the vector according to the third aspect of the present invention into a host cell to obtain the host cell according to the fourth aspect of the present invention.
[0056] In some embodiments, the method of introducing includes but is not limited to: lipofection, microinjection, electroporation, DNA vector, RNA vector, retroviral vector, lentiviral vector, poxvirus vector, herpes simplex virus vector, adenovirus vector and / or adeno-associated virus vector, etc.
[0057] In addition, the present invention also provides a method for treating and / or preventing hypothyroidism during pregnancy, treating and / or preventing diabetes, improving hypothyroidism and / or improving abnormal glucose metabolism or blood sugar levels.
[0058] Furthermore, the method comprises the following steps: administering to a subject in need thereof a therapeutically and / or preventively effective amount of the polypeptide or pharmaceutically acceptable salt thereof described in the first aspect of the present invention, the polynucleotide described in the second aspect of the present invention, the vector described in the third aspect of the present invention, the host cell described in the fourth aspect of the present invention, the polypeptide derivative described in the fifth aspect of the present invention, the pharmaceutical composition described in the sixth aspect of the present invention and / or the pharmaceutical preparation described in the seventh aspect of the present invention.
[0059] In the present invention, the subject includes mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other apes and monkeys; farm animals such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs and cats; laboratory animals, including rodents such as rats, mice and guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, etc. In one embodiment of the present invention, the subject is a human. The term subject includes confirmed patients.
[0060] In the present invention, the effective amount refers to the amount of the drug, pharmaceutical composition or pharmaceutical preparation that effectively produces the desired preventive, alleviating or therapeutic effect. Depending on the active ingredients (in the present invention, in particular, the polypeptide or pharmaceutically acceptable salt thereof described in the first aspect of the present invention, the polynucleotide described in the second aspect of the present invention, the vector described in the third aspect of the present invention, the host cell described in the fourth aspect of the present invention and / or the polypeptide derivative described in the fifth aspect of the present invention), symptoms and their severity, the age of the treated mammal and other factors, the amount of the drug, pharmaceutical composition or pharmaceutical preparation described in the present invention to achieve the effective amount will also vary accordingly, but the specific amount can be routinely determined by a person of ordinary skill in the art based on the knowledge in the field mastered by him / her and the contents disclosed in the present invention, and the dosage that can produce the above-mentioned effects is within the scope of protection of the present invention.
[0061] In some embodiments, the administration of the drug, pharmaceutical composition or pharmaceutical preparation can be carried out in any form, illustratively, the mode of administration includes but is not limited to: oral, topical, intravenous, intradermal, intramuscular, transdermal, intraarterial, intraperitoneal, intralesional, intracranial, intraarticular, intraprostatic, intrapleural, intratracheal, intranasal, intravitreal, intrarectal, subcutaneous, subconjunctival, intravesical, transmucosal, intrapericardial, intraumbilical, intraocular, by inhalation, by injection, by infusion, by continuous infusion, by catheter, by lavage, in cream, or in a suitable formulation. The selection of the specific method of administration and the selection of the dosage form of the pharmaceutical preparation can vary according to a variety of factors (e.g., the substance administered and the severity of the disease or condition being treated).
[0062] In some embodiments, the drug, pharmaceutical composition or pharmaceutical preparation may be administered to the subject by oral administration, injection or topical administration. For example, the method may include administering the drug, pharmaceutical composition or pharmaceutical preparation to the subject three times a day, once a day, once every two days, etc. In some embodiments, injection administration may include subcutaneous injection, intramuscular injection, intravenous injection, etc. In some embodiments, injection administration may include injecting the drug, pharmaceutical composition or pharmaceutical preparation directly into the lesion or in an area near the lesion. In some embodiments, a combination of different administration methods may be used.
[0063] Compared with the prior art, the present invention has the following beneficial effects:
[0064] (1) The present invention discovered for the first time a polypeptide PDMHS2 that can improve insulin secretion and proliferation function, and confirmed through experiments that it can promote the expression of proliferation-related gene Ki67, insulin gene Insulin and thyroid hormone receptor THRβ in pancreatic islet cells of offspring with hypothyroidism during pregnancy.
[0065] (2) The polypeptide PDMHS2 provided by the present invention is highly conservative and highly stable. The polypeptide PDMHS2 is highly conserved in different species, indicating that it plays an important role in evolution. At the same time, its high stability means that it remains active in the body for a long time, which is conducive to the long-term application of the drug.
[0066] (3) The polypeptide PDMHS2 provided by the present invention has cell permeability. The polypeptide PDMHS2 can enter pancreatic islet cells, which is an important characteristic of it as a drug molecule because it can act directly on pancreatic islet cells without passing through other cells or tissues.
[0067] (4) The polypeptide PDMHS2 provided by the present invention has the ability to regulate the thyroid hormone receptor THRβ. THRβ plays an important role in regulating metabolism. The polypeptide PDMHS2 helps to improve metabolic problems related to hypothyroidism by upregulating the expression of THRβ.
[0068] (5) The polypeptide PDMHS2 provided by the present invention has the property of enhancing the expression of insulin gene. Insulin is a key hormone for controlling blood sugar levels. Increasing the expression of insulin gene is helpful for treating diseases related to abnormal glucose metabolism such as diabetes.
[0069] (6) The polypeptide PDMHS2 provided by the present invention has the property of promoting the proliferation of pancreatic islet cells. The polypeptide PDMHS2 promotes the proliferation of pancreatic islet cells by upregulating the expression of the Ki67 gene in pancreatic islet cells, which is essential for maintaining pancreatic islet function and secreting sufficient insulin.
[0070] (7) The polypeptide PDMHS2 provided by the present invention can be used to treat hypothyroidism during pregnancy. Poor nutrition or environment in the early stage of life (1000 days) will increase the risk of diabetes in offspring. Considering the impact of hypothyroidism during pregnancy on fetal development, the application of polypeptide PDMHS2 provides a new treatment strategy for patients with hypothyroidism during this special period.
[0071] (8) The polypeptide PDMHS2 provided by the present invention can be used in the treatment of diabetes. In the field of diabetes treatment, finding new drug targets and treatment methods has always been the focus of research. The polypeptide PDMHS2 provides a new treatment plan for the treatment of diabetes, which has important scientific significance and clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 : Comparison of OGTT plasma glucose concentrations between the control group and the MH group, (A) OGTT plasma glucose concentrations of male offspring in the gestational hypothyroidism group (MH) and the normal control group (Control) at 4 weeks of age; (B) Glucose AUC of male offspring in the gestational hypothyroidism group (MH) and the normal control group (Control) at 4 weeks of age; (C) OGTT plasma glucose concentrations of male offspring in the gestational hypothyroidism group (MH) and the normal control group (Control) at 8 weeks of age; (D) Glucose AUC of male offspring in the gestational hypothyroidism group (MH) and the normal control group (Control) at 8 weeks of age (* p < 0.05).
[0073] Figure 2: Analysis of differentially expressed peptide characteristics in the serum of pregnant women with hypothyroidism during pregnancy, (A) scatter plot of serum peptide analysis; (B) analysis of the number of up-regulated and down-regulated peptides; (C) analysis of the number of peptides of different lengths; (D) cluster analysis of 18 candidate peptides with large differences between groups and small differences within groups; (E) GO biological process enrichment analysis of differential peptide precursor proteins; (F) KEGG pathway enrichment analysis of differential peptide precursor proteins.
[0074] Figure 3 : Preliminary screening of functional peptides, (A) Effects of candidate peptides on the expression of Ki67, a gene related to pancreatic islet cell proliferation; (B) Effects of PDMHS2 on the mRNA expression of THRβ1, THRβ2, Insulin 1, and Insulin 2; (C) Effects of PDMHS2 on the expression of proteins Ki67, THRβ, and Insulin.
[0075] Figure 4 : Characteristic analysis of PDMHS2 polypeptide, (A) Conservation analysis of PDMHS2 in humans, mice and rats; (B) Cell entry analysis of PDMHS2 polypeptide.
[0076] Figure 5 :Analysis of the functional mechanism of PDMHS2, (A) Silver staining results of the eluate of PDMHS2 affinity chromatography column; (B) Analysis of the expression of the candidate target protein DNMT3A in the eluate.
[0077] Figure 6 : Expression of DNMT3A protein and related detection of target gene THRβ after PDMHS2 polypeptide treatment, (A) Expression of DNMT3A mRNA in pancreatic islet cells of normal pregnant mice and offspring of hypothyroidism during pregnancy; (B) Expression of DNMT3A protein in pancreatic islet cells of normal pregnant mice and offspring of hypothyroidism during pregnancy; (C) MSP-PCR primer design; (D) MSP-PCR results of THRβ promoter region in pancreatic islet cells of normal pregnant mice and offspring of hypothyroidism during pregnancy; (E) ChIP-PCR results of THRβ promoter region in pancreatic islet cells of normal pregnant mice and offspring of hypothyroidism during pregnancy; (F) MSP-PCR results of THRβ promoter region after control polypeptide and polypeptide intervention; (G) ChIP-PCR results of THRβ promoter region after control polypeptide and polypeptide intervention. DETAILED DESCRIPTION
[0078] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and cannot be understood as limiting the present invention. It can be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents.
[0079] The reagents and raw materials used in the present invention are easily obtained by ordinary technicians in the field and can be obtained from commercial channels unless otherwise specified. The experimental methods in the present invention that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. In particular, the following examples are only used to illustrate the present invention and should not limit the scope of the present invention in any way.
[0080] Example Screening of polypeptide PDMHS2 and its application in improving insulin secretion and proliferation function
[0081] 1. Screening of Peptide PDMHS2
[0082] (1) Peptide extraction
[0083] Serum was collected from patients with hypothyroidism during pregnancy and healthy pregnant women during the same period. Peptides were extracted by Covaris crushing and ultrafiltration method, and differentially expressed peptides were screened by iTRAQ labeling combined with LC-MS / MS technology. The peptide extraction process was as follows: ① Ultrafiltration was performed using a 10 kd ultrafiltration tube, the flow-through was collected, and the peptides were dried using a refrigerated centrifugal concentrator dryer; ② Add an appropriate amount of 0.1% TFA to fully dissolve; ③ Desalt using an OasisHLB desalting column; ④ Dry the peptides using a refrigerated centrifugal concentrator dryer; ⑤ Add an appropriate amount of 50% ACN+0.5% TFA to fully dissolve; ⑥ Desalt using an OasisMCX desalting column; ⑦ Dry the peptides using a refrigerated centrifugal concentrator dryer; ⑧ Take 1 / 10 of the sample and use 50 μL of distilled water to fully dissolve the peptides; ⑨ Use the PierceQuantitative Colorimetric Peptide Assay quantitative kit for concentration determination.
[0084] (2) Sample concentration detection
[0085] This project uses the BCA method to detect sample concentration. The operation process is as follows:
[0086] ① Prepare standard solution: Use the standard protein provided by the ThermoScientific Pierce BCA kit to prepare different concentrations of bovine serum albumin BSA according to its operating method. The standard solution is shown in Table 1 below;
[0087] Table 1 Standard solution
[0088]
[0089] ② Prepare a standard curve: Use a SPECTRAMAX microplate reader to read the absorbance at 480 nm;
[0090] ③ Sample concentration determination: The sample type for this project is blood. The specific determination results are shown in Table 2 below.
[0091] Table 2 Sample concentration
[0092]
[0093] (3) Sample quality inspection report evaluation
[0094] The test results show that the sample concentration and total amount meet the requirements through NanoDrop2000 peptide quantification.
[0095] Based on the principles of high expression abundance, stable half-life, and conservation among species, we selected four peptides and named them Peptide derived from maternal hypothyroidism serum 1-4 (PDMHS 1-4). We isolated and cultured primary pancreatic islet cells from male offspring (0 and 8 weeks old) of pregnant hypothyroidism rats, added the above four chemically synthesized peptides to the cell culture medium (with the solvent as the control), and the peptide concentration was 50 µM to verify their effects on the expression of proliferation-related gene Ki67, insulin gene Insulin, and thyroid hormone receptor THRβ in pancreatic islet cells of pregnant hypothyroidism rats. The results showed that only the polypeptide PDMHS2 could promote the mRNA expression of the proliferation-related gene Ki67 in the primary pancreatic islet cells of the offspring of gestational hypothyroidism (0 weeks and 8 weeks old), while the other three polypeptides had no obvious effect; and the polypeptide PDMHS2 could promote the mRNA expression of THRβ1, THRβ2, Insulin 1, and Insulin 2, and promote the expression of Ki67, Insulin, and THRβ proteins.
[0096] With the help of UniProt online analysis, it was found that the PDMHS2 polypeptide was derived from the 1st to 14th amino acids of the amino terminus of the human Caveolae-associated protein 2 protein, and was highly conserved in humans, mice, and rats. The FITC fluorescent-labeled PDMHS2 polypeptide was synthesized at a concentration of 50 µM and added to the culture supernatant of primary pancreatic islet cells of the offspring of gestational hypothyroidism (0 weeks). After 24 hours, it was found that the polypeptide could enter the pancreatic islet cells and enter the cell nucleus to exert its effect.
[0097] 2. Experimental methods
[0098] (1) Preparation of experimental reagents: 0.02% PTU solution: add 20 mg PTU to 100 mL of natural drinking water.
[0099] (2) Experimental animals: A total of 85 SPF-grade 6-week-old Sprague-Dawley (SD) female rats were purchased from Anlimao Biotechnology Co., Ltd. and raised by the Experimental Animal Center of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine. The experimental animal center is an SPF-grade animal room with good ventilation and air filtration systems, a constant temperature of 22±3℃ and a constant humidity of 24±6% throughout the year, and a light and dark cycle of 12 h each. Sterilized cages and bedding were replaced twice a week, and water bottles and animal rooms were cleaned and disinfected regularly.
[0100] (3) Feed and drinking water: Feeds are divided into ordinary growth feed and breeding feed, both of which are SPF grade. Rats in cages and lactating rats are fed breeding feed, and pups are fed ordinary growth feed after weaning, all of which are purchased from Nanjing Xietong Animal Food Company. All rats have free access to sterilized drinking water.
[0101] (4) Construction of animal model: Female SD rats were adaptively raised to 180-220 g and randomly divided into a control group and a hypothyroidism group, with 30 rats in the control group and 50 rats in the hypothyroidism group. The hypothyroidism group consumed drinking water containing 0.02% propylthiouracil (PTU), while the control group consumed regular drinking water. Blood was collected from the retroorbital vein on days 0, 3, 7, 14, and 21 of medication. When the serum TSH was higher than that of the normal group and T4 was lower than that of the normal group, the hypothyroidism model was considered to be successful. After the model was successfully established, all rats were caged in a 1:1 ratio of male to female, and female rats were housed separately after vaginal plugs appeared.
[0102] Newborn mice were weighed, their toes were clipped and marked, the mice born from hypothyroid mothers were used as the experimental group, and the mice born from normal mothers were used as the control group. They were raised in separate cages after weaning. The two groups of mice were weighed regularly after birth, and relevant animal experiments were performed at 0, 4, and 8 weeks of age.
[0103] (5) Oral glucose tolerance test (OGTT): 1) At 5 pm on the day before the experiment, rats were individually moved into clean cages, food was removed, and rats were numbered. They were fasted for 16 h overnight until 9 am the next day. During the fasting period, rats maintained normal drinking water. 2) Prepared items: rat cages and wood shavings, labels, weight scales, recording forms, blood glucose test strips, high glucose solution, 1 mL / 5 mL syringes, gavage needles, scissors, pens, numbered test tubes, capillary blood collection tubes, cotton balls, gloves, masks, etc. 3) OGTT started at 9 am the next day. Weigh and record the weight of each rat. Use a pen to mark the serial number at the base of the rat's tail. 4) Determination of fasting basal blood glucose: Remove the rat from the cage, use the orbital blood sampling method, and measure the fasting blood glucose with a blood glucose meter. The measured value is considered to be the blood glucose value at 0 min. 5) After the rats were allowed to adapt for 30 min, glucose gavage was prepared. The volume of glucose solution required for each rat was calculated = body weight (g) / 1000 (4 mL), accurate to 0.01 mL, i.e. 50% glucose, gavage at 2 g / kg (4 mL / kg) body weight. 6) The timing was started from the moment the gavage was completed, and the blood glucose level of each rat at each time point was measured according to the operation of step 4) at 15 min, 30 min, 60 min, and 120 min. 7) After the experiment, each cage of rats was supplemented with feed. The experimental results were analyzed using Graphpad Prism 5.0 software.
[0104] (6) Islet extraction: 1) Preparation: sterilize instruments, prepare alcohol cotton balls, sterilize serum bottles, and fast the animals for 16 hours. Prepare collagenase just before use and keep it on ice away from light. 2) Anesthetize rats by weight, generally 1 mL / rat. Injection site: groin. Use 2% sodium pentobarbital and calculate the required volume according to 50 mg / kg. Rinse the syringe with HBSS, then draw up the collagenase solution and place it on ice. 3) Tie up the rat on the operating table. Wet the abdomen with alcohol cotton balls. 4) Cut the fur first, then cut the muscle layer, and open the chest to expose the heart, taking care to avoid abdominal bleeding. Find the opening of the pancreatic duct to the duodenum (duodenal ampulla) and wait for the suture to be ligated. 5) Cut the right atrial appendage to drain venous blood and wipe the blood inside the abdominal cavity. When the bleeding is good, the liver can be seen to turn white. 6) Find the common hepatic duct near the end of the liver and prepare for cannulation. At the opening of the common bile duct, gently clamp the common bile duct with forceps and insert the cannula. Before inserting the cannula, the syringe should be vented. The amount of collagenase V (1 mg / mL) (or Liberase RI) to be injected (7-8 mL) should be determined according to the filling of the pancreas. First, slowly fill 2 mL, and then fill it slightly faster to ensure that the pancreatic house is completely filled. 7) After the pancreatic tail is completely filled, carefully cut off the filled pancreas white intestine, and pay attention to keep the pancreas intact and not broken. Sequence: First find the pancreatic tissue from the lower right colon, and find the spleen and pancreatic tail connected in the upper right direction of the line of sight; one person clamps the colon, and the other person cuts the connection between the pancreas and the intestine in the direction of the intestine, and stops when cutting at the common mesentery, taking care to avoid cutting the blood vessels; then turn over the intestinal tissue to find the duodenum, and cut the tissue along the direction of the gastric fundus. Finally, one person picks up the spleen, and the other person assists in picking up the entire pancreatic tissue, quickly placing it in a pre-cooled 50 mL sterilized plastic centrifuge tube, and then immediately placing it on ice. 8) After all animals are dissected, add about 2-5 mL of collagenase V (1 mg / mL) (or Liberase RI) to a 50 mL tube and digest at 37°C for 28 min. 9) Remove the 50 mL tube from the water bath and immediately place it on ice. Vortex until the tissue is broken into a sandy state, 3 times for 5 seconds; add 2 times the volume of ice-cold HBSS containing serum, invert and mix, and terminate the digestion reaction. 10) Pass through a 30-mesh sieve to remove incompletely digested tissue blocks. Centrifuge at 1000 rpm (acceleration: 9, deceleration: 9), 2 min, 4°C. 11) Discard the supernatant, add ice-cold HBSS (without serum), centrifuge at 1000 rpm (acceleration: 9, deceleration: 9), 2 min, 4°C. 12) Discard the supernatant, add 5 mL of Histopaque, and mix by pipetting (using a pipette). Carefully use a 10 mL syringe to slowly add 5 mL of HBSS to the upper layer of the liquid along the wall of the tube, and the solution will separate into two layers. Centrifuge at 2000 rpm (acceleration: 9, deceleration: 1) for 20 min at 4°C. 13) Add HBS containing serum to the 6-well plate.14) After centrifugation, separate the tubes into layers, carefully aspirate the granular white sandwich layer between the two layers, and place them in a 6-well plate pre-filled with HBSS (containing serum). Perform rough picking (select yellow cell clusters) under a stereomicroscope to count islets. 15) After repeated picking, select islets with moderate size and no debris and place them in sugar-free and phenol-free DMEM + 10% FBS + double antibody + Glucose 11 mM culture medium, culture overnight and prepare for fine picking (or use RPMI1640 + 10% FBS + double antibody + Glucose 11mM for culture). 16) After 12 hours, you can perform fine picking and grouping, and prepare for experimental drug treatment.
[0105] (7) Real-time PCR to determine gene expression
[0106] 1) Extraction of total RNA from tissue: Use TRIzol reagent to extract total RNA from pancreatic tissue according to the instructions. The specific steps are as follows:
[0107] ① Turn on the ice machine, clean the mortar and dry it, and put it in a -20℃ refrigerator to freeze. The entire RNA extraction process is carried out on ice. ② Take 500 islets, add 1 mL Trizol, grind it into a homogenate with a mortar and suck it into a 1.5 mL EP tube. ③ Add 200 μL chloroform (trichloromethane), shake vigorously for 15-20 s, and let it stand at room temperature for 2-3 min. ④ Centrifuge at 4℃, 12000rpm, centrifuge for 10 min. ⑤ Carefully transfer the upper supernatant to a new EP tube, about 400-500 μL. ⑥ Add an equal volume of isopropanol, mix gently 4-5 times, let it stand at room temperature for 3 min, and then centrifuge it at 4℃, 12000 rpm for 10 min. ⑦ Gently pour off the supernatant, gently aspirate the residual liquid with a 20 μL pipette, wash the precipitate with 1 mL 75% ethanol 1-2 times, vortex to mix, and centrifuge at 4°C, 12000 rpm for 5 min. ⑧ Discard the supernatant and dry the precipitate at room temperature for 5-10 min. ⑨ Add 50 μL of nuclease-free water to the precipitate, pipette several times to dissolve the RNA, and measure the concentration. ⑩ Determine whether to dilute it again with nuclease-free water based on the measured concentration.
[0108] 2) Reverse transcription of RNA
[0109] ① Reverse transcription reaction
[0110] The reverse transcription system was prepared according to the instructions of the commercial chemical kit and 20 μL of the system was prepared on ice as shown in Table 3 below.
[0111] Table 3 Reaction system
[0112]
[0113] ② Reverse transcription reaction procedure
[0114] The reverse transcription reaction procedure is shown in Table 4 below.
[0115] Table 4 Reaction procedure
[0116]
[0117] 3. Experimental results
[0118] (1) Effects of maternal hypothyroidism on offspring glucose metabolism
[0119] The results of the oral glucose tolerance test (OGTT) showed that the fasting blood glucose levels and glucose levels at each observation time after glucose loading in the MH group of 4-week-old male offspring were no different from those in the control group. The blood glucose levels of the two groups of rats reached the highest peak at 15 minutes after glucose loading, and then gradually decreased. At 120 minutes after glucose loading, the blood glucose level dropped to close to the fasting blood glucose level ( Figure 1 There was no significant difference in the area under the blood glucose curve (AUC) between the two groups ( Figure 1 When the two groups of mice grew to 8 weeks of age, the OGTT results were as follows: Figure 1 As shown in Figure C, the fasting blood glucose level of male offspring in the MH group was higher than that in the control group (8.13 ± 0.38 vs 6.63 ± 0.19 mmol / L, p < 0.05). The blood glucose concentration of both groups of offspring reached a peak 15 min after glucose loading, and then gradually decreased. At 120 min after glucose loading, the blood glucose concentration dropped to close to the fasting blood glucose level, and the trend of blood glucose at each time point was similar to that of the control group. However, the blood glucose of offspring in the MH group was significantly higher than that of the control group at 15 min of OGTT (14.34 ± 1.21 vs 17.84 ± 0.81 mmol / L, p < 0.05). The area under the blood glucose curve in the MH group was significantly higher than that in the control group (1399 ± 35.46 mmoL L -1 (120min) -1 vs 1239 ± 31.7 mmoL -1 (120min) -1 , p < 0.05, Figure 1 D in), where L -1 (120min) -1 It refers to the area under the blood glucose (mmol / L) curve within 120 minutes (120 min).
[0120] (2) Analysis of differentially expressed peptide characteristics in the serum of pregnant women with hypothyroidism during pregnancy
[0121] Serum from pregnant women with hypothyroidism who were first seen at the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine (Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine) was collected, and serum from healthy pregnant women of the same period was randomly used as a control. Peptides were extracted by Covaris crushing and ultrafiltration, and differentially expressed peptides were screened using iTRAQ labeling combined with LC-MS / MS technology. The results showed that: ① A total of 575 peptides were detected. Compared with the normal group, 58 peptides were significantly overexpressed in the serum of pregnant women with hypothyroidism (fold change ≥ 1.5, p < 0.05), and 80 peptides were significantly underexpressed (fold change ≤ 0.67, p < 0.05) ( Figure 2 A in Figure 2 B in the above); ② The length of the polypeptide is mainly 11-15 amino acids ( Figure 2 C in the figure); ③ 18 peptides showed large differences between groups and small differences within groups, and can be used as candidate peptides for subsequent research ( Figure 2 D in ); ④ GO and KEGG functional enrichment analysis showed that the differentially expressed peptide protein precursors were mainly involved in cellular protein metabolism, actin skeleton regulation, PI3K-Akt, PPAR signaling pathways, etc. ( Figure 2 E in Figure 2 F in.
[0122] (3) Preliminary screening of functional peptides
[0123] For the above 18 candidate peptides ( Figure 2 D in the table), based on the principles of high expression abundance, stable half-life, and conservation among species, we selected 4 peptides (see Table 5 below). For the convenience of subsequent research, they were named Peptide derived from maternal hypothyroidism serum 1-4 (PDMHS1-4). Bioinformatics analysis showed that these 4 peptides were conserved and stable among species (the corresponding sequences are shown in Table 5 below), of which 3 peptides (PDMHS1-3) were differentially low expressed in the serum of patients with hypothyroidism during pregnancy, and 1 peptide (PDMHS4) was differentially high expressed in the serum of patients with hypothyroidism during pregnancy. Based on the previously constructed classic rat gestational hypothyroidism research model and the research group's previous method of islet cell isolation, we isolated and cultured primary islet cells from male offspring (0 and 8 weeks old) of rats with gestational hypothyroidism, and added the above four chemically synthesized peptides to the cell culture medium (with the solvent as the control), with the peptide concentration of 50 µM, to verify their effects on the expression of proliferation-related gene Ki67, insulin gene Insulin and thyroid hormone receptor THRβ in islet cells of gestational hypothyroidism offspring. The results showed that only the peptide PDMHS2 could promote the mRNA expression of proliferation-related gene Ki67 in primary islet cells of gestational hypothyroidism offspring (0 and 8 weeks old), while the other three peptides had no significant effect ( Figure 3 A in the figure); and the polypeptide PDMHS2 can promote the mRNA expression of THRβ1, THRβ2, Insulin 1, and Insulin 2 ( Figure 3 B in the figure), promoting the expression of Ki67, Insulin, and THRβ proteins ( Figure 3 C in.
[0124] Table 5 Basic characteristics of candidate peptides PDMHS1-4
[0125]
[0126] (4) Characteristic analysis of PDMHS2 peptide
[0127] Using UniProt online analysis, we found that the PDMHS2 peptide is derived from the 1st to 14th amino acids of the amino terminus of human Caveolae-associated protein 2 protein and is highly conserved in humans, mice, and rats ( Figure 4 A in the figure); PDMHS2 peptide labeled with FITC was synthesized at a peptide concentration of 50 µM and added to the culture supernatant of primary pancreatic islet cells of rats with hypothyroidism during pregnancy (week 0). After 24 hours, it was found that the peptide could enter the pancreatic islet cells and the cell nucleus ( Figure 4 B in the figure).
[0128] (5) Analysis of the functional mechanism of PDMHS2
[0129] We used the peptide pull-down method to screen molecules that interact with PDMHS2. Biotin-labeled PDMHS2, control Scramble (HAFKGMPEDQAAEQ (SEQ ID NO:5)), blank control (Control-1), and solvent control (Control-2) were incubated with streptavidin magnetic beads (Dynabeads™ M-280 Streptavidin, Thermofisher Scientific), and then co-incubated with primary pancreatic islet cell protein lysate of gestational hypothyroidism offspring (0 weeks). The eluate was subjected to electrophoresis and silver staining, and differential bands (1, indicated by the box) were selected for mass spectrometry identification and analysis ( Figure 5 A in the figure). A total of 8 proteins were identified, among which DNMT3A (DNA-methyltransferase 3A) had a strong mass spectrometry signal with significant differences and a size consistent with the position of the cut band (130 kDa). Western blot was further used to verify the expression of DNMT3A in the above protein eluate. The results showed that DNMT3A protein was significantly enriched in the eluate of PDMHS2 ( Figure 5Therefore, we speculated that DNMT3A is a potential target of PDMHS2.
[0130] (6) DNMT3A protein expression and target gene THRβ-related detection after PDMHS2 peptide treatment
[0131] We first analyzed the effect of peptide PDMHS2 intervention (using Scramble peptide as control) on the expression level of DNMT3A in primary pancreatic islet cells of gestational hypothyroidism offspring (week 0). The results showed that the mRNA and protein expression levels of DNMT3A did not change ( Figure 6 A in Figure 6 B in the figure). UCSC analysis revealed the presence of a CpG island in the promoter region of the rat THRβ gene, and the methylation specific PCR (MSP-PCR) primers were further designed using the software Methprimer ( Figure 6 C in the figure, indicated by a red box). First, the DNA methylation level of DNMT3A protein in the THRβ promoter region of primary pancreatic islet cells of normal pregnant mouse offspring and offspring with gestational hypothyroidism (0 weeks) was analyzed. MSP-PCR was performed after genomic DNA was treated with sodium bisulfite. Agarose gel electrophoresis analysis revealed that the DNA methylation level in the THRβ promoter region was increased in the offspring with gestational hypothyroidism (0 weeks) ( Figure 6 D and U in the table represent unmethylated primer pairs, and M represents methylated primer pairs). DNMT3A antibodies were used to incubate the protein lysates of primary pancreatic islet cells from normal pregnant mouse offspring and offspring with gestational hypothyroidism (week 0), respectively. The enrichment of DNMT3A protein in the THRβ promoter region was detected by ChIP-PCR. The results showed that the enrichment of DNMT3A protein in the THRβ promoter region was high in the offspring with gestational hypothyroidism (week 0). Figure 6 E in.
[0132] The genomic DNA of primary islet cells of gestational hypothyroidism offspring (week 0) treated with Scramble or PDMHS2 was further extracted. The genomic DNA was treated with sodium bisulfite and then subjected to MSP-PCR. Agarose gel electrophoresis analysis revealed that the DNA methylation modification level of the THRβ promoter region in the PDMHS2-treated group was reduced ( Figure 6 F in the figure). DNMT3A antibodies were further used to incubate with the control peptide and the peptide PDMHS2-treated primary pancreatic islet cell protein lysate of the offspring of gestational hypothyroidism (week 0), and the enrichment of DNMT3A protein in the THRβ promoter region was detected by ChIP-PCR. The results showed that the enrichment of DNMT3A protein in the peptide PDMHS2-treated group was reduced ( Figure 6The above results indicate that PDMHS2 affects the expression of the target gene THRβ by affecting the DNA methylation modification of DNMT3A, thereby affecting the proliferation of pancreatic β cells and the level of insulin synthesis.
Claims
1. A polypeptide or a pharmaceutically acceptable salt thereof capable of improving insulin secretion and proliferation function, characterized in that: The amino acid sequence of the polypeptide is shown in SEQ ID NO:
1.
2. A polynucleotide, characterized in that The polynucleotide encodes the polypeptide according to claim 1.
3. A carrier, characterized in that The vector comprises the polynucleotide according to claim 2.
4. A host cell, characterized in that The host cell comprises the vector of claim 3.
5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the polypeptide according to claim 1 or a pharmaceutically acceptable salt thereof, the polynucleotide according to claim 2, the vector according to claim 3 and / or the host cell according to claim 4.
6. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises the pharmaceutical composition according to claim 5.
7. Use of the polypeptide according to claim 1 or a pharmaceutically acceptable salt thereof, the polynucleotide according to claim 2, the vector according to claim 3 and / or the host cell according to claim 4 in the preparation of a medicament for treating and / or preventing diabetes.
8. A method for producing the polypeptide of claim 1, comprising the steps of culturing the host cell of claim 4, and isolating the polypeptide of claim 1 from the cell culture obtained by culturing.
